Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals

Mass production of low-cost, generic direct-acting antivirals (DAAs) will be required to achieve targets of eliminating hepatitis C (HCV) by 2030. The pharmaceutical companies Gilead and Bristol-Myers Squibb have granted voluntary licences (VLs) to generic companies to mass produce the DAAs sofosbuv...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Virus Erad
Autors principals: Hill, Andrew, Tahat, Loai, Mohammed, Mohammed Khalil, Tayyem, Rabab Fayez, Khwairakpam, Giten, Nath, Sanjay, Freeman, James, Benbitour, Ismahane, Helmy, Sherine
Format: Artigo
Idioma:Inglês
Publicat: Mediscript Ltd 2018
Matèries:
Short Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5892672/
https://ncbi.nlm.nih.gov/pubmed/29682307
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars